Your Time
KST(UST+9)
| Time | Room A | Room B | Room C | Room D | |
|---|---|---|---|---|---|
| 8:40-9:00 | Opening Ceremony | Oral / Poster Presentation & Exhibition |
|||
| 09:00-10:30 |
ASCO/KSMO Joint Symposium 1 Integrating next-generation sequencing into clinical practices: Sharing the real-world experiences |
Scientific Symposium 1
Immunotherapy beyond anti-PD1/PDL1 antibody |
Scientific Symposium 2
Resistance mechanism of immunotherapy |
Satellite Symposium 1 (09:00-09:40) 
From science to Real-world data(RWD) with breast cancer patient
|
|
|
Satellite Symposium 2 (09:50-10:30) 
Management of mPaCa patients : Focused on Liposomal Irinotecan(ONIVYDE)
|
|||||
| 10:30-10:50 | Break (20 min.) | ||||
| 10:50-11:30 |
Plenary Lecture 1
Checkpoint blockade therapy for melanoma: Combinations to improve outcomes Jedd D. WOLCHOK (USA) |
||||
| 11:30-12:10 |
Luncheon Symposium 1
Front-line therapy for advanced NSCLC immunotherapy and immunotherapy combinations
|
Luncheon Symposium 2
Changing the treatment landscape for gastric and GEJ cancer: Nivolumab plus chemotherapy
|
Luncheon Symposium 3
First bevacizumab biosimilar in Korea, ONBEVZI
|
||
| 12:10-12:40 | Break (30 min.) | ||||
| 12:40-14:10 |
Scientific Symposium 3
Clinical application of ctDNA profile |
Scientific Symposium 4
Targeting endocrine pathway: Breast & prostate |
Satellite Symposium 3 (12:40-13:10)
The Welcome rain, Pembrolizumab: New hope for MSI-H/dMMR colorectal cancer patients
|
Collaborative Symposium 1 (12:40-13:20) Moving forward to a new paradigm of treatment in advanced gastric cancer |
|
|
Satellite Symposium 4 (13:30-14:10) 
The evolving HCC treatment landscape: What is the role of LENVIMA
|
Satellite Symposium 5 (13:30-14:10) 
TAS-102, New therapeutic option for patients with CRC / GC
|
||||
| 14:10-14:30 | Break (20 min.) | ||||
| 14:30-15:30 |
Scientific Symposium 5
Recent advances in stomach cancer & GIST |
Oncology Multi-Disciplinary Symposium KOR
Multidisciplinary approach for patients with brain metastasis |
KCSG/KSMO Joint Symposium Conducting phase I clinical trial with targeted therapy/immunotherapy |
Oral Discussion 1
Breast cancer / Head&Neck cancer |
|
| 15:30-15:50 | Break (20 min.) | ||||
| 15:50-17:20 |
JSMO/KSMO Joint Symposium Biomarker driven clinical trials : Sharing experiences |
ESMO/KSMO Joint Symposium Updates of IO treatments and Asian subgroup analysis in oncology clinical trials |
Scientific Symposium 6
Recent advances in NSCLC & SCLC |
Satellite Symposium 6 (15:50-16:30) 
Shifting perception in treatment of advanced renal cell carcinoma
|
|
|
Satellite Symposium 7 (16:40-17:20) 
Evolving treatment landscape with CDK 4/6 inhibitors in metastatic breast cancer
|
|||||
| 17:20-18:00 |
Plenary Lecture 2
Cancer clinical trials and cancer patients care during or after COVID-pandemic Giuseppe Curigliano (Italy) |
||||
| Time | Room A | Room B | Room C | Room D | |
|---|---|---|---|---|---|
| 09:00-09:40 |
Plenary Lecture 3
Non-genetic cancer therapy resistance: A cell biologist's perspective Joan S Brugge (USA) |
Oral / Poster Presentation & Exhibition |
|||
| 09:40-10:00 | Break (20 min.) | ||||
| 10:00-11:30 |
ASCO/KSMO Joint Symposium 2 Ladder of cancer treatment: Precision medicine and palliative care |
KOSRO/KSMO Joint Symposium De-escalation/escalation of radiotherapy |
Special Symposium 1
A new path to cardiotoxicity management in the age of precision medicine |
Satellite Symposium 8 (10:00-10:40) 
The evolving ALK+ NSCLC paradigm: The future of 1st line and beyond
|
|
|
Satellite Symposium 9 (10:50-11:20)
KEYTRUDA® for 1L TNBC – A new hope that blooms in the wild land
|
|||||
| 11:30-12:10 |
Luncheon Symposium 4
Tecentriq + Avastin : Reigniting progress in the HCC treatment landscape
|
Luncheon Symposium 5
Paradigm-changing treatment strategy for lung cancer covering early to advanced stages
|
Collaborative Symposium 2 The development of RAS/RAF targeted drugs |
||
| 12:10-12:40 | Break (30 min.) | ||||
| 12:40-14:00 |
Scientific Symposium 7
Recent advances in Hepatocellular carcinoma/Pancreas-Biliary Ca |
Scientific Symposium 9
Expanding indications of PARP inhibitors |
Multidisciplinary Oncology Team Education Session 1
KOR Advances in toxicity management |
Satellite Symposium 10 (12:40-13:20) 
Optimal treatment strategy in metastatic colorectal cancer
|
|
|
Satellite Symposium 11 (13:20-14:00) 
From clinical trials to practice: New era of EGFRm NSCLC treatment, LECLAZA®
|
|||||
| 14:00-14:20 | Break (20 min.) | ||||
| 14:20-15:50 |
KSSO/KSMO Joint Symposium Multimodality treatment strategy: Primary breast surgery in stage IV breast cancer; Neoadjuvant chemotherapy followed by surgery in locally advanced pancreatic cancer |
KSP/KSMO Joint Symposium Tumor microenvironment and pathology |
Multidisciplinary Oncology Team Education Session 2
KOR Current strategies for maximizing the benefit of immunotherapy |
Satellite Symposium 12 (14:20-15:00) 
What is being considered for treatment decision for 2nd line mCRC?
|
|
|
Satellite Symposium 13 (15:10-15:50) 
Optimal bone health management with BTA in bone metastatic solid tumor
|
|||||
| 15:50-16:00 | Break (10 min.) | ||||
| 16:00-17:00 |
Scientific Symposium 8
Infection and cancer: HBV, HIV, HPV, CMV etc |
KSR/KSMO Joint Symposium State-of-the-art oncologic imaging analysis |
Multidisciplinary Oncology Team Education Session 3
KOR Targeted therapy : Clinical effects and resistance |
Oral Discussion 2
Hepato-biliary-pancreatic cancer/GI cancer/Lung cancer |
|
| 17:00-17:40 |
Plenary Lecture 4
Drug development: The revolution of the last 15 years Jean-Charles SORIA (USA) |
||||
| 17:40-18:00 | Closing Ceremony & Awards | ||||
